ATRIAL FIBRILLATION AND FLUTTER IN HYPERTROPHIC CARDIOMYOPATHY

Aim. To find out the factors associated with atrial fibrillation/flutter (AF) in patients with hypertrophiccardiomyopathy.
Material and methods. Totally 182 HCMP patients included, of those 103 — men (mean age 59,6±14,6y). Diagnosis of AFwas set using ECG or Holter monitoring of ECG using medical charts with the mentioned anamnesis of AF Results. Paroxysmal or permanent form of AF were found in 60 (33%) patients. AF patients were older (64,2±11,2 vs 57,3±15,6 y, p=0,005), with more significant symptomatics(CHFFCbyNYHA2,4±0,8vs2,1±0,8, p=0,02). In AF patients the size of left atrium (LA) was larger than in sinus patients (4,5±0,6 vs 4,1±0,7 cm, p=0,00003). Prevalence of outgoing tract of the left ventricle (OTLV) was nearly same in both groups (50% vs 52,2%, p=0,2), and maximum pressure gradient (PGmax) in OTLV was higher in AF patients (46,0±48,0 vs 21,8±26,6 mmHg, p=0,02). There is and increase of AF with the age (r=0,21, p=0,005), severity of symptoms (r=0,2, p=0,001), LAenlargement(r=0,44, p=0,04), severity of pulmonary hypertension (r=0,47, p=0,004), value of PGmax in OTLV (r=0,23, p=0,02). With the method of binary logistic regression 3 main variables were selected as the most of predictable value for AF: age, LA size, PGmax in OTLV. The model defined that makes to estimate the risk of AF with high diagnostic probability — x 22,0, df=3 (p=0,00006): AF = 0,05307 * age + 0,98065 * LA + 0,01516 * Рймакс in OTLV - 8,66. With the result >0 there is a high risk of AF, and if <0 — the risk of AF is minimum.
Conclusion. The model invented for risk prediction in AF in HCMP patients using three predictors: patient age, left atrium diameter and maximum gradient of pressure in OTLV.

1. Gersh В, Магоп В, Bonow R et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Circulation 2011; 124: 783-831.

2. Ageev FT, Gabrusenko SA, Postnov AJu, et al. National clinical guideline on diagnosis and treatment of hypertrophic cardiomyopathy. Eurasian heart journal 2014; 3: 5-23. Russian (АгеевФ.Т., ГабрусенкоС.А., ПостновА.Ю. и др. Клинические рекомендации по диагностике и лечению кардиомиопатий (гипертрофическая). Евразийский кардиологический журнал 2014; 3: 5-23).

3. Belenkov JuN, Privalova EV, KaplunovaVJu M. Hypertrophic Cardiomyopathy: textbook for physicians: GJeOTAR-Media; 2011. Russian (Беленков Ю.Н., Привалова Е.В., Каплуно ва В. Ю. Гипертрофическая кардиомиопатия: руководство для врачей. М.: ГЭОТАР-Медиа;2011).

4. Komissarova SM, Vajhanskaja TG, Shket AP. National guideline. Diagnosis and treatment of primary hypertrophic cardiomyopathy. Belarusan Ministry of Health. Republic research and clinical center "Cardiology". Belarusan society of cardiologists. Minsk; 2010. Russian (Комиссарова СМ., Вайханская Т. Г., Шкет А.П. Национальные рекомендации. Диагностика и лечение первичной гипертрофической кардиомиопатий. Министерство здравоохранения Республики Беларусь. Республиканский научно-практический центр "Кардиология". Белорусское научное общество кардиологов. Минск2010;36с).

5. Panov АА, Maleeva AV, Kuz'mina GV, et al. Hypertrophic Cardiomyopathy. Astrakhan J Med 2009; 4, 3: 85-8. Russian (Панов А. А., Малеева А. В., Кузьмина Г. В. и др. Гипертрофическая кардиомиопатия. Астраханский медицинский журнал 2009; 4, 3: 85-88).

6. Tian T, Wang Y, Sun К et al. Clinical profile and prognostic significance of atrial fibrillation in hypertrophic cardiomyopathy. Cardiology 2013; 126(4): 258-64.

7. Link MS. Avoid atrial fibrillation in patients with hypertrophic cardiomyopathy. Cardiology 2014; 127(1): 51-2.

8. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a practice guidelines and the heart rhythm society report of the ACC/AHA. Circulation, 2014. March.

9. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal/ P. 2733-2779. doi:10.1093/eurheartj/ehu284. (29 August 2014).

10. Guttmann OP, Rahman MS, O'Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 2014; 100(6): 465-72.

11. GirasisC, Vassilikos V, EfthimiadisGK, et al. Patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation: advanced echocardiographic evaluation of the left atrium combined with non-invasive P-wave analysis. Eur Heart J Cardiovasc Imaging 2013; 14(5):425-34.

12. SiontisKC,Geske JB,Ong K. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc 2014; 3(3):e001002.doi: 10.1161/JAHA.114.001002.

13. Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy Circulation 200; 104(21): 2517-24.